Factors affecting therapeutic drug monitoring
Upcoming SlideShare
Loading in...5
×
 

Factors affecting therapeutic drug monitoring

on

  • 1,367 views

 

Statistics

Views

Total Views
1,367
Views on SlideShare
1,367
Embed Views
0

Actions

Likes
3
Downloads
21
Comments
3

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Factors affecting therapeutic drug monitoring Factors affecting therapeutic drug monitoring Presentation Transcript

  • FACTORSAFFECTINGTHERAPEUTICDRUGMONITORINGSeptember28, 20121BY : VIJIT AGRAWAL5th Pharm.DJSSCP, Mysore
  • INTRODUCTION Therapeutic drug monitoring (TDM) is generallydefined as the clinical laboratory measurementof a chemical parameter that, with appropriatemedical interpretation, will directly influencedrug prescribing procedures by combiningknowledge ofpharmaceutics, pharmacokinetics, andpharmacodynamics.September 28, 20122
  • CLINICAL USEFULNESS OF TDM1. Maximize efficacy of drug2. Avoiding toxicity3. Identifying therapeutic failure4. Facilitating dose adjustment5. Facilitating therapeutic effectsSeptember 28, 20123
  • Factors Affecting TDM1. Patient demographics2. Patient Compliance3. Individuals capacity toabsorb/distribute/metabolize/excretethe drug4. Genetic factorsSeptember 28, 20124
  • Factors Affecting TDM…5. Concomitant disease, Tropical diseaseand nutritional deficiencies6. Alternative system of medicine7. Ethnic differences and extrapolation ofthe normal rangeSeptember 28, 20125
  • Factors Affecting TDM…8. Alcohol & Tobacco use9. Quality of medication and genericformulation10. Control of drug assay11. Medication or sampling errors12. Laboratory errors13. Cost effectivenessSeptember 28, 20126
  • 1. Patient demographics Age, sex and lean body weight areparticularly important for renally cleareddrugs as knowledge of these allowscalculation of creatinine clearance. Ethnicity may be an importantconsideration for TDM of some hepaticallycleared drugs.September 28, 20127
  • 2. Patient Compliance If the concentration of the drug is lowerthan expected, the possibility of noncompliance should be considered beforea dose increase is recommended.September 28, 20128
  • 3. Individuals capacity toabsorb/distribute/metabolize/excrete the drugAbsorption:The rate of absorption and extent of absorptionare dependent on various factors such as: Drug formulation Manufacturer Route of administration Intra-individual variations Another aspect of absorption isbioavailability. This is the fraction of theadministered dose that reaches the systemiccirculation. Bioavailability is 100% for IV injection.September 28, 20129
  • Distribution:(Vd) = dose/plasma concentrationThe absolute bioavailability of a drug, whenadministered by an extra vascular route, isusually less than one (i.e. F<1). For example if a drug has a half life of fourhours, four hours after the initial dose, 50%of the drug will be removed. Eight hours after the initial dose, half of theremaining drug (25% of total) will beremoved, for a total of 75% having beenremoved at that time, and so on.September 28, 201210
  •  Half-life information is used to determinethe correct drug dose required to attainthe desired therapeutic range.September 28, 201211
  • Metabolism: In addition, drug metabolites can beeither protein bound (inactive) or free(active). The drug dosage will depend on how thedrug metabolizes. Factors that impact drug metabolismincludesgenetics, environment, nutrition, and age.September 28, 201212
  • Excretion: Drug excretion from the body occursthrough the kidneys, or fluids excretedthrough the lungs, GI or skin. Renal dysfunction reduces drugclearance and may contribute to drugaccumulation and increased risk ofadverse drug effects.September 28, 201213
  • Some other causes Age: In general, drugs metabolized moreslowly in foetal, neonatal, and geriatricpopulations Physical properties of the drug(hydrophobicity, pKa, solubility) If the drug is administered in a fed orfasted state Gastric emptying rateSeptember 28, 201214
  •  Interactions with other drugs (e.g.antacids, alcohol, nicotine) Interactions with other foods (e.g.grapefruit juice, pomello, cranberry juice)September 28, 201215
  • Enzyme induction/inhibition by otherdrugs/foods:- Enzyme induction (increase rate ofmetabolism). e.g.Phenytoin, barbiturates, carbamazepine,glutethimide, primidone, rifampicininduces CYP1A2, CYP2C9, CYP2C19 andCYP3A4, , which is involved in a drugsmetabolism may reduce the drugsactivitySeptember 28, 201216
  • Enzyme inhibition (decrease rate ofmetabolism), resulting in ↑ drugactivity, e.g. Protease inhibitors, Nitrogenmustard, Mtx, Cidenafil Citrate Prolonging the action of variousdrugs, includingchloramphenicol, cimetidine, disulfiram(Antabuse), isoniazid, methyldopa, metronidazole, phenylbutazone Grape fruit juice inhibits CYP3A --> highernifedipine concentrationsSeptember 28, 201217
  •  Individual Variation in MetabolicDifferences Phenotypic differences, inter hepaticcirculation, diet, gender.September 28, 201218
  • 4. Genetic factors It plays an as yet poorly defined role intherapeutic drug monitoring, as is thecase of the poor ability of some racialgroups to acetylated drugsSeptember 28, 201219
  • 5. Concomitantdisease, Tropical disease andnutritional deficienciesThis includes diseases highly prevalent indeveloping countries such as Infections, Diarrhoea, Worm infestations, Tuberculosis, Nutritional deficiencies, plus a Higher proportion of patients with diabetesand AIDSSeptember 28, 201220
  •  Nutritional deficiencies are oftensubclinical and escape detection andthey have been shown to affect drugpharmacokinetics.September 28, 201221
  • 6. Alternative system ofmedicineSeptember 28, 201222 India is unique in having atleast three systems ofmedicine coexisting with‘western’ medicine(allopathy);ayurveda, homeopathy andunani. A patient with a history ofgeneralized tonic-clonic (GTC)seizures, well controlled andwith plasma phenytoin levelswithin the therapeuticrange, presented with suddenloss of seizure control.
  •  History revealed that he was taking‘shakhapushpi’ and plasma analysisshowed that his phenytoin level haddropped. Interaction with conventional drugs havebeen documented forliquorice, ginseng, tannicacids, plantain, uzara root, hawthorn andkyushin all of which may be prescribed bypractitioners of the alternative systems.September 28, 201223
  • 7. Ethnic differences The fact that interpopulation variations in drugpharmacokinetics can result in higher or lowerplasma drug concentrations is well known. Mani has reported that the effectiveanticonvulsant dosage may be lower in Indiansthan in EuropeansSeptember 28, 201224
  • 8. Alcohol & Tobacco use Chronic use of alcohol has been shown tocause non-specific hepatic microsomalenzyme induction, resulting in increasedclearance and decreased serumconcentrations of hepatically cleareddrugs such as Phenytoin.September 28, 201225
  •  Cigarette smoking increases the hepaticclearance of theophylline and patientswho have recently stopped smoking mayhave unexpectedly high theophyllineconcentrations.September 28, 201226
  • 9. Quality of medication andgeneric formulation Quality of products (drugcontent, bioavailability) is importantespecially for drugs with a narrow marginof safety which is just those drugs forwhich TDM is relevant. Authors have already reported fromPakistan and Vietnam that quality ofdrugs used may be substandard andneed additional quality control.September 28, 201227
  • 10. Quality control in drugassays For TDM programs, quality control is vitallyimportant and in developing countriesthere are hardly any procedures forlaboratory accreditation or externalquality control.September 28, 201228
  •  In view of the mushrooming of private‘pathobiochem’ laboratories which offera range of pathology and biochemicalinvestigations, the state Food and DrugAdministration’s are proposing laboratoryinspections for standardizing and ensuringquality of results. There are no such proposals for drugassay laboratories.September 28, 201229
  • 11. Medication or samplingerrors In cases where the TDM result isincompatible with drug administrationrecords, the possibility of a medication orsampling error should be considered. For Example, the drug may have beengiven to the wrong patient, or blood mayhave been mistakenly drawn from apatient in a neighbouring bed.September 28, 201230
  • 12. Laboratory errorsSeptember 28, 201231 If a laboratory error issuspected, thelaboratory should becontacted andasked to repeat theassay. Alternatively, a newblood sample can bedrawn and sent to adifferent laboratoryfor assay.
  • 13. Cost effectiveness Rapid and cost-effective measurement ofmost drugs for which TDM is indicated canbe achieved using commercial kits run onautomated analysers using a number ofdifferent methodologies includingfluorescence polarisation immunoassay.September 28, 201232
  • References A Textbook of Clinical Pharmacy Practice (Second Edition)G Parthasarathi, Karin Nyfort-Hansen & Milap C Nahata (Eds.)2012; 331 pp; 978-81-7371-756-7 Therapeutic drug monitoring in a developing country: anoverviewN J Gogtay, N A Kshirsagar, S S Dalvi Br J Clin Pharmacol. 1999November; 48(5): 649–654. doi: 10.1046/j.1365-2125.1999.00088.xPMCID: PMC2014358Web link:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014358/ Therapeutic drug monitoring D.J. Birkett, Professor of ClinicalPharmacology, Flinders University of South Australia, AdelaideWeb link:http://www.australianprescriber.com/magazine/20/1/9/11/ Therapeutic Drug Monitoring (TDM) - An Educational GuideWeb link:http://www.medical.siemens.com/siemens/en_GLOBAL/gg_diag_FBAs/files/products_disease_states/TDM/TDM_Guide_FINAL.pdfSeptember 28, 201233
  • September 28, 201234Thank You